← Back to Search

Unknown

Drug: TT-01025-CL for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by LG Chem
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights

Study Summary

A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of TT-01025-CL in Healthy Subjects

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events
Secondary outcome measures
AUC
Cmax
Terminal half-life

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Drug: TT-01025-CLExperimental Treatment1 Intervention
TT-01025-CL
Group II: Drug: PlaceboPlacebo Group1 Intervention
Placebo of TT-01025-CL

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

LG ChemLead Sponsor
62 Previous Clinical Trials
30,377 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~15 spots leftby Apr 2025